CSIMarket
 


China Yct International Group, Inc.  (CYIG)
Other Ticker:  
 

China Yct International Group's Leverage Ratio

CYIG's quarterly Leverage Ratio and Total Liabilities, Equity growth


Despite a net increase in borrowings by 2.43%, China Yct International Group managed to enhance Leverage Ratio in the third quarter 2018 to 0.05, falling below the company's typical Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2018, 30 other companies have achieved lower Leverage Ratio than China Yct International Group in the III Quarter 2018. While Leverage Ratio total ranking has improved so far in the third quarter 2018 to 112, from total ranking in the second quarter 2018 at 114 .

Explain Leverage Ratio?
Who are CYIG Customers?
What are CYIG´s Total Liabilities?


CYIG Leverage Ratio (Dec 31 2018)
III. Quarter
(Sep 30 2018)
II. Quarter
(Jun 30 2018)
I. Quarter
(Mar 31 2018)
IV. Quarter
(Dec 31 2017)
III. Quarter
Y / Y Equity Change 10.44 % 13.76 % 18.82 % 27.42 % 25.53 %
Y / Y Total Liabilities Change 26.99 % -23.22 % -32.37 % -35.75 % 163.61 %
Leverage Ratio MRQ 0.05 0.05 0.04 0.05 0.04
CYIG's Total Ranking # 112 # 114 # 77 # 93 # 97
Seq. Equity Change 4.43 % 0.08 % -0.8 % 6.54 % 7.56 %
Seq. Total Liabilities Change 2.43 % 16.57 % -10.98 % 19.48 % -38.07 %



Leverage Ratio third quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 31
Healthcare Sector # 39
Overall Market # 112


Leverage Ratio Statistics
High Average Low
0.36 0.06 0.01
(Dec 31 2011)   (Jun 30 2013)




Financial Statements
China Yct International Group's Equity $ 112 Millions Visit CYIG's Balance sheet
China Yct International Group's Total Liabilities $ 5 Millions Visit CYIG's Balance sheet
Source of CYIG's Sales Visit CYIG's Sales by Geography


Cumulative China Yct International Group's Leverage Ratio

CYIG's Leverage Ratio for the trailling 12 Months

CYIG Leverage Ratio

(Dec 31 2018)
III. Quarter
(Sep 30 2018)
II. Quarter
(Jun 30 2018)
I. Quarter
(Mar 31 2018)
IV. Quarter
(Dec 31 2017)
III. Quarter
Y / Y Equity TTM Growth 10.44 % 13.76 % 18.82 % 27.42 % 25.53 %
Y / Y Total Liabilities TTM Growth 26.99 % -23.22 % -32.37 % -35.75 % 163.61 %
Leverage Ratio TTM 0.05 0.04 0.05 0.06 0.07
Total Ranking TTM # 75 # 22 # 22 # 22 # 11
Seq. Equity TTM Growth 4.43 % 0.08 % -0.8 % 6.54 % 7.56 %
Seq. Total Liabilities TTM Growth 2.43 % 16.57 % -10.98 % 19.48 % -38.07 %


On the trailing twelve months basis Due to the net new borrowings of 2.43% during the trailing twelve months finishing in the III Quarter 2018, cumulativeLeverage Ratio improved to 0.05, a new company high.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 5, during the past 12 months, other companies have achieved lower Leverage Ratio than China Yct International Group. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2018, compared to the prior period, from 22 to 75.

Explain Leverage Ratio?
Who are CYIG Customers?
What are CYIG´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 6
Healthcare Sector # 10
Within the Market # 75


trailing twelve months Leverage Ratio Statistics
High Average Low
0.05 0.02 0.01
(June 30. 2013)   (Sep 30 2014)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2018, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2018 MRQ Total LiabilitiesDec 31 2018 MRQ Equity
Synlogic Inc   0.13 $ 15.974  Millions$ 124.098  Millions
Phio Pharmaceuticals Corp   0.13 $ 1.744  Millions$ 13.578  Millions
Acadia Pharmaceuticals Inc   0.13 $ 61.123  Millions$ 479.079  Millions
Calithera Biosciences Inc   0.13 $ 16.011  Millions$ 126.714  Millions
Oncternal Therapeutics Inc   0.13 $ 3.279  Millions$ 26.111  Millions
Dicerna Pharmaceuticals Inc   0.13 $ 25.162  Millions$ 200.693  Millions
Intra cellular Therapies Inc   0.12 $ 39.492  Millions$ 317.715  Millions
Forty Seven Inc   0.12 $ 16.216  Millions$ 133.221  Millions
Astria Therapeutics inc   0.12 $ 4.227  Millions$ 34.942  Millions
Unity Biotechnology Inc   0.12 $ 19.094  Millions$ 160.693  Millions
Corcept Therapeutics Inc  0.12 $ 32.291  Millions$ 275.882  Millions
Oramed Pharmaceuticals Inc   0.12 $ 3.345  Millions$ 28.858  Millions
Gw Pharmaceuticals Plc  0.12 $ 77.752  Millions$ 674.080  Millions
Tonix Pharmaceuticals Holding Corp   0.11 $ 2.655  Millions$ 23.664  Millions
Neurotrope inc   0.11 $ 2.957  Millions$ 26.521  Millions
Agile Therapeutics Inc  0.11 $ 2.218  Millions$ 20.174  Millions
Epizyme Inc.  0.11 $ 25.386  Millions$ 233.009  Millions
Sage Therapeutics Inc   0.10 $ 89.734  Millions$ 862.971  Millions
Morphosys Ag  0.10 $ 56.438  Millions$ 546.977  Millions
Marinus Pharmaceuticals Inc   0.10 $ 6.909  Millions$ 68.325  Millions
Urovant Sciences Ltd   0.10 $ 10.094  Millions$ 102.158  Millions
Aldeyra Therapeutics Inc   0.10 $ 8.473  Millions$ 86.618  Millions
Immune Design Corp.  0.10 $ 8.955  Millions$ 92.005  Millions
Procyon Corporation  0.10 $ 0.198  Millions$ 2.051  Millions
Aadi Bioscience Inc   0.09 $ 5.457  Millions$ 58.667  Millions
Vanda Pharmaceuticals Inc   0.09 $ 25.277  Millions$ 275.422  Millions
Nanoviricides inc   0.08 $ 1.164  Millions$ 13.841  Millions
Dianthus Therapeutics Inc   0.08 $ 11.665  Millions$ 145.648  Millions
Global Blood Therapeutics Inc.  0.08 $ 44.844  Millions$ 572.799  Millions
Diamedica Therapeutics Inc   0.08 $ 1.314  Millions$ 17.025  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com